DDInter839 DDInter1676
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Goserelin {u} (Compound) resembles {v} (Compound) Pentagastrin
Goserelin {u} (Compound) resembles {v} (Compound) Cetrorelix
Goserelin {u} (Compound) treats {v} (Disease) breast cancer
Goserelin {u} (Compound) binds {v} (Gene) LHCGR
Goserelin {u} (Compound) upregulates {v} (Gene) SPAG4
Goserelin {u} (Compound) is included by {v} (Pharmacologic Class) Gonadotropin Releasing Hormone Receptor Agonists
Goserelin {u} (Compound) causes {v} (Side Effect) Reaction aggravation
Goserelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Goserelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Goserelin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Goserelin (Compound) resembles Pentagastrin (Compound)
Goserelin (Compound) resembles Cetrorelix (Compound)
Goserelin (Compound) treats breast cancer (Disease)
Goserelin (Compound) binds LHCGR (Gene)
Goserelin (Compound) upregulates SPAG4 (Gene)
Goserelin (Compound) is included by Gonadotropin Releasing Hormone Receptor Agonists (Pharmacologic Class)
Goserelin (Compound) causes Reaction aggravation (Side Effect)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Goserelin may lead to a major life threatening interaction when taken with Dolasetron